Molecular Weight(MW): 307.14
Histamine acts directly on the blood vessels to dilate arteries and capillaries mediated by both H 1- and H 2-receptors.
Purity & Quality Control
Choose Selective Histamine Receptor Inhibitors
|Description||Histamine acts directly on the blood vessels to dilate arteries and capillaries mediated by both H 1- and H 2-receptors.|
|Features||Histamine phosphate is indicated as a diagnostic aid for evaluation of gastric acid secretory function.|
Histamine (10 μM) gives a larger inositol monophosphate accumulation in bovine adrenal chromaffin cells. Histamine (10 μM) stimulates the level of radioactivity into the InsP3-containing fraction in bovine adrenal chromaffin cells. Histamine (100 μM) stimulates incorporation into the InsP3-containing eluate in a less extent than for angiotensin I1 and bradykinin. 
|In vivo||Histamine phosphate (0.025 mg/kg) produces a mean increase in basilar blood flow of 145% of control in dogs. Histamine phosphate produces considerable increases in basilar blood flow as well as a decrease in femoral arterial blood pressure in dogs when injected intravenously and measured with an electromagnetic flow transducer.  Histamine phosphate (4 μg/kg) causes lymph flow to increase from 6.0 to 27.0 (SEM) ml/h in unanesthetized sheep. Histamine phosphate (4 μg/kg) also causes increases in lung water, pulmonary vascular resistance, arterial PCO2, pH, and hematocrit, and decreases in cardiac output and arterial PO2 in unanesthetized sheep.  Histamine phosphate (8.3 mg/kg/min) causes no significant change in pulmonary lymph flow (QL) or protein concentration (CL) in anesthetized open-chested dogs, however, both are increased after alloxan. Histamine phosphate (8.3 mg/kg/min) also causes no significant change in the pulmonary capillary membrane filtration coefficient (Kf) and the maximum capillary pressure (PCcritical) in anesthetized open-chested dogs.  Histamine phosphate (50 mg/kg) produces a pronounced rise in acid secretion but the output of pepsin remained unchanged in the unanaesthetized intact rat. Histamine phosphate (50 mg/kg) produces maximal stimulation of gastric acid secretion and is free from toxic effects in the unanaesthetized intact rat. |
|In vitro||Water||42 mg/mL (136.74 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03050866||Not yet recruiting||Circulating Tumor Cell|Metastatic Prostate Cancer||Erasmus Medical Center|Sanofi||February 2017||Phase 2|
|NCT02905019||Recruiting||Malaria||University of Oxford||August 2016||Phase 1|Phase 2|
|NCT02882217||Recruiting||Asthma||EURRUS Biotech GmbH||August 2016||Phase 1|
|NCT02889159||Recruiting||Photoaged Skin|Normal Skin||University of Michigan||June 2016||--|
|NCT02613910||Terminated||Pemphigus||GlaxoSmithKline||December 2015||Phase 3|
|NCT02021474||Unknown status||Migraine Prophylaxis||BioHealthonomics Inc.||September 2015||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.